- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Clinical Subjects Office Chief Steps Down
17 October 2002 (All day)
After heading efforts to beef up patient safety in clinical trials for 2 years, the director of the federal Office for Human Research Protections (OHRP) is returning to academia in December. Greg Koski, a Harvard University anesthesiologist, came in to head the newly promoted OHRP within the Department of Health and Human Services (HHS) after a death in a gene therapy trial brought increased scrutiny of patient safety in research.
Since Koski's arrival, OHRP has cracked down on several institutions for violating patient safety protections and has cleared a backlog of investigations. Koski also developed what he calls a "proactive, performance-based system" for helping institutions do a better job. The idea is to have institutions grade themselves on their patient protections programs, just as factories strive to achieve gold stars for quality control, Koski says. A report earlier this month from the Institute of Medicine helps complete the "road map" on where to go next, he notes, partly by calling for voluntary accreditation of human subjects protection programs.
University of Kansas bioethicist Mary Faith Marshall calls the quality-assurance program "fantastic" and says Koski was a "tireless ambassador," traveling the country to win over "the hearts of many people in the research community" with his message of "shared goals." Some patient advocates, however, are pushing for mandatory standards instead of the voluntary approach that Koski has supported.
Koski, who will serve through the end of November, insists that his departure "is not a political decision in any way" and notes that he was on a 2-year leave from Harvard in Massachusetts, where his family still lives. However, some observers suggest that a lack of support at HHS might have helped speed his return to academe. Recently, HHS abruptly decided to let the charter of OHRP's advisory committee lapse, a decision that Marshall, the panel's chair, says "shocked and dismayed" members and surprised Koski as well. HHS is now reforming the group and is said to be expanding its charter to include protection of fetuses and embryos, in line with the antiabortion views of the Bush Administration.